FDA Approves Brigatinib to Treat Frontline ALK-Positive NSCLC

The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non –small cell lung cancer, as detected by an FDA-approved test.

Source: CancerNetwork - May 22, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news